CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
41.51
+0.98 (2.42%)
At close: Jan 21, 2025, 4:00 PM
41.70
+0.19 (0.46%)
After-hours: Jan 21, 2025, 6:54 PM EST
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for CRSP stock have an average target of 77.13, with a low estimate of 48 and a high estimate of 105. The average target predicts an increase of 85.81% from the current stock price of 41.51.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRSP stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 9 | 9 | 9 | 9 | 9 | 9 |
| Sell | 2 | 2 | 2 | 2 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $84 | Strong Buy | Reiterates | $84 | +102.36% | Jan 14, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $98 → $85 | Strong Buy | Maintains | $98 → $85 | +104.77% | Jan 7, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $86 | Buy | Reiterates | $86 | +107.18% | Dec 20, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $94 | Strong Buy | Maintains | $94 | +126.45% | Dec 10, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $53 | Hold | Reiterates | $53 | +27.68% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
16.36M
from 371.21M
Decreased by -95.59%
Revenue Next Year
134.84M
from 16.36M
Increased by 724.16%
EPS This Year
-5.26
from -1.94
EPS Next Year
-5.12
from -5.26
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 105.0M | 692.6M | 5.7B | |||
| Avg | 16.4M | 134.8M | 642.2M | |||
| Low | 1.6M | n/a | 46.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -71.7% | 4,133.1% | 4,138.4% | |||
| Avg | -95.6% | 724.2% | 376.3% | |||
| Low | -99.6% | - | -65.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.16 | -3.29 | 8.47 | |||
| Avg | -5.26 | -5.12 | -3.18 | |||
| Low | -6.57 | -6.71 | -7.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.